OIS@AAO 2017 Videos
Aura Biosciences is preparing to conduct a Phase IIa trial of its light-activated AU-011 therapy for treatment of ocular melanoma, CEO Elisabet de los Pinos,…
Read MorePresenting results from the initial Phase I/II mitochondrial gene therapy for ND4 Leber’s hereditary optic nerve (LHON), GenSight’s Barrett Katz, MD, chief medical officer, stressed…
Read MoreThe TrueVision “story” is one of digital surgery, which allows for overlays, incorporating robotics, and incorporation of preoperative diagnostics. It’s a “virtual surgical cockpit that…
Read MoreThe minimally invasive glaucoma surgery (MIGS) market is expected to grow from about $164 million in 2017 to $521 million by 2022, Ivantis CEO and…
Read MoreThis privately held company has a “pipeline of products” to treat glaucoma, concentrating on the MINIject, a “next-generation” minimally invasive glaucoma surgery (MIGS) device. The…
Read MoreThe FluidVision AIOL is the first “true shape-changing, fluid-driven intraocular lens (IOL),” according to PowerVision, which means it creates a continuously variable monofocal lens and…
Read MoreZepto – Mynosys’ capsulotomy device used in a one-time method – was launched in India, Australia, Germany, and the US in 2017. The US clinical…
Read MoreAvedro uses noninvasive strengthening of the cornea with topical drops and photoactivation without surgery or implants to reshape the cornea through cross-linking. The two major…
Read MoreA five-minute noninvasive transscleral treatment: Aciont’s Visual XP is used to deliver molecules passively. Another treatment, Visual XI, is based on iontopheresis and enables the…
Read MoreEyeGate Pharma is taking two technology platforms quickly through to commercialization, CEO Stephen From said. The first is a hyaluronic acid (HA) the company is…
Read MoreNovaliq’s mission is to “transform ocular therapeutics” using a proprietary water-free platform to accomplish the goal. A key limitation of water-based technologies is bioavailability, which…
Read MoreBio-Tissue is the pioneer of the birth tissue industry, said CTO Scheffer Tseng. Biotissue is cryopreserved, and boasts anti-inflammation, anti-scarring, anti-angiogenesis, and promotion of wound…
Read MoreSUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.